<DOC>
	<DOCNO>NCT02685605</DOCNO>
	<brief_summary>INTRAGO II resemble multicentric , prospective , randomize , 2-arm , open-label clinical phase III trial test median progression-free survival ( PFS ) patient newly diagnose glioblastoma multiforme ( GBM ) improve addition intraoperative radiotherapy ( IORT ) standard radiochemotherapy .</brief_summary>
	<brief_title>Intraoperative Radiotherapy Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Age ≥18 ≤ 70 year 2 . Karnofsky Performance Score ( KPS ) ≥ 60 % 3 . Supratentorial T1Gd enhance lesion ( ) amenable total resection 4 . Legal capacity ability subject understand character individual consequence clinical trial 5 . Patient 's write informed consent obtain least 24h prior surgery 6 . For woman childbearing potential : adequate contraception 7 . Patients must adequate organ function Bone marrow function : Platelets ≥ 145.000/μL WBC ≥ 4.000/μL Hemoglobin ≥ 12.0 g/dL Liver Function : ASAT ALAT ≤ 1.5 time ULN ALP ≤ 2.5 time ULN Total Serum Bilirubin &lt; 1 time ULN Renal Function : Serum Creatinine ≤ 1.5 time ULN Inclusion Criteria Related Surgery : 8 . IORT must technically feasible 9 . Histologically confirm ( frozen section ) GBM ( WHO grade IV ) Exclusion Criteria 1 . Multicentric disease ( e.g . hemisphere ) nonresectable satellite lesion 2 . Previous cranial radiation therapy 3 . Cytostatic therapy / chemotherapy cancer within past 5 year 4 . Use alternate electrical field ( e.g. , NovoTTF ) 5 . History cancer comorbidities limit life expectancy less five year 6 . Previous therapy antiangiogenic substance ( bevacizumab ) 7 . Technical impossibility use MRI know allergy MRI and/or CT contrast agent 8 . Participation clinical trial test cancerderived investigational agents/procedures . 9 . Pregnant breast feeding patient 10 . Fertile patient refuse use safe contraceptive method study Exclusion Criteria Related Surgery : 11 . Active egress fluid ventricular defect 12 . Infield risk organ and/or IORT dose &gt; 8 Gy risk organ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Intraoperative Radiotherapy</keyword>
	<keyword>Radiotherapy Dose Escalation</keyword>
</DOC>